Banco BTG Pactual’s Moderna MRNA Stock Holding History

Banco BTG Pactual’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-60	Closed	-$10.8K	–	169
2022 Q4	$10.8K	Buy	+60	New	+$9.81K	0.01%	149

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Banco BTG Pactual's MRNA Position: Q4 2023 in Review

Banco BTG Pactual sold out of Moderna (MRNA) in Q4 2023, closing a stake of 4,346 shares — an estimated $449K sold.

Banco BTG Pactual first reported a position in MRNA in Q1 2020 and held it in 6 quarters. The position peaked at $759K in Q4 2022. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

Banco BTG Pactual reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
Banco BTG Pactual sold 4,346 Moderna shares in Q4 2023, an estimated $449K.
Banco BTG Pactual first reported a position in Moderna in Q1 2020 and held it in 6 quarters.
Banco BTG Pactual's Moderna position peaked at $759K in Q4 2022.
884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Banco BTG Pactual's 13F filing for Q4 2023, filed 12 Feb 2024.